Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion. clinicaltrials.gov/study/NCT064...
clinicaltrials.gov
ClinicalTrials.gov
